dronedarone (SR33589); placebo
Проводит Sanofi
Страница компанииA Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00174785/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 70 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 4628 чел. во всех странах исследования.
- Плановая дата окончания (03.2008) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 8 · невключение: 19
Критерии включения
- 1\. Patients aged 75 years or older (70 years before protocol amendment 1), or patients aged at least 70 years (any age before protocol amendment 1) with one or more of the following risk factors at baseline:
- Hypertension (taking antihypertensive drugs of at least two different classes)
- Diabetes
- Prior cerebrovascular accident (stroke or transient ischemic attack) or systemic embolism
- Left atrium diameter greater than or equal to 50 mm by echocardiography
- Left ventricular ejection fraction less than 0.40 by 2D-echocardiography (two-dimensional echocardiography)
- 2\. Availability of one electrocardiogram (ECG) within the last 6 months, showing that the patient was or is in AF/AFL
- 3\. Availability of one ECG within the last 6 months, showing that the patient was or is in sinus rhythm
Критерии невключения
- General criteria:
- 1\. Refusal or inability to give informed consent to participate in the study
- 2\. Any non cardiovascular illness or disorder that could preclude participation or severely limit survival including cancer with metastasis and organ transplantation requiring immune suppression
- 3\. Pregnant women (pregnancy test must be negative) or women of childbearing potential not on adequate birth control: only women with a highly effective method of contraception \[oral contraception or intra-uterine device (IUD)\] or sterile can be randomized.
- 4\. Breastfeeding women
- 5\. Previous (2 preceding months) or current participation in another clinical trial with an investigational drug (under development) or with an investigational device
- 6\. Previous participation in this trial
- Criteria Related to a cardiac condition:
- 7\. Patients in permanent atrial fibrillation
- 8\. Patients in unstable hemodynamic condition such as acute pulmonary edema within 12 hours prior to start of study medication; cardiogenic shock; treatment with intra-venous pressor agents; patients on respirator; congestive heart failure of stage NYHA IV (New York Heart Association classification) within the last 4 weeks; uncorrected, hemodynamically significant primary obstructive valvular disease; hemodynamically significant obstructive cardiomyopathy; a cardiac operation or revascularization procedure within 4 weeks preceding randomization
- 9\. Planned major non-cardiac or cardiac surgery or procedures including surgery for valvular heart disease, coronary artery bypass graft (CABG) , percutaneous coronary intervention (PCI) , or on urgent cardiac transplantation list
- 10\. Acute myocarditis or constrictive pericarditis
- 11\. Bradycardia < 50 bpm and/or PR-interval > 0.28 sec on the last 12-lead ECG
- 12\. Significant sinus node disease (documented pause of 3 seconds or more) or 2nd or 3rd degree atrioventricular block (AV-block) unless treated with a pacemaker
- Criteria Related to Concomitant Medications:
- 13\. Need of a concomitant medication that is prohibited in this trial, including the requirement for Vaughan Williams Class I and III anti-arrhythmic drugs, that would preclude the use of study drug during the planned study period
- Criteria Related to Laboratory Abnormalities:
- 14\. Plasma potassium < 3.5 mmol/l (as anti-arrhythmic drugs can be arrhythmogenic in patients with hypokalemia, this must be corrected prior to randomization)
- 15\. A calculated Glomerular Filtration Rate (GFR) at baseline <10 ml/min using the Cockroft Gault formula
Источник: ClinicalTrials.gov, NCT00174785 · запись обновлена в реестре 12 января 2010.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 3
- First Hospitalization for Cardiovascular Reason or Death From Any Cause — minimum follow-up duration: 1 year ; maximum: 2.5 years
Цель исследования
To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL).
To assess that dronedarone is well tolerated in this population.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00174785 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.